GlassScriptPhysician profile
Alaina Mandrapilias
NPI 1932760691
$2,643.84
in general payments reported to CMS, 2019-2025
26 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $121 · 2023: $1,153 · 2024: $1,040 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,523.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.69 | 2022-2025 | |
| Lilly USA, LLC | $324.70 | 2023-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $242.84 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $199.10 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $173.21 | 2023-2024 | Farxiga, Airsupra |
| Intuitive Surgical, INC. | $121.23 | 2024 | |
| Eisai INC. | $115.33 | 2024 | |
| Janssen Scientific Affairs, LLC | $113.75 | 2023 | Stelara |
| Smith+Nephew, INC. | $106.83 | 2024 | Grafix Pl, Stravix |
| Pfizer INC. | $106.14 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.83 | 2023-2025 | Xifaxan |
| Amgen INC. | $89.22 | 2023-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $75.26 | 2023-2025 | Cologuard Collection Kit |
| Irhythm Technologies, INC. | $63.79 | 2023 | Zio Xt Patch |
| Bayer Healthcare Pharmaceuticals INC. | $61.02 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.14 | 2023-2024 | Caplyta |
| Inspire Medical Systems, INC. | $51.47 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $37.65 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.48 | 2022 | |
| Sumitomo Pharma America, INC. | $25.81 | 2023 | Gemtesa |
| Dexcom, INC. | $22.89 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $22.07 | 2024 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $19.68 | 2023 | Eliquis |
| Phathom Pharmaceuticals, INC. | $18.04 | 2024 | Voquezna |
| Amarin Pharma, INC. | $17.78 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaina Mandrapilias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.